SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:research.chalmers.se:dba13e4b-207a-46bc-b71b-ee7ee759181d"
 

Sökning: onr:"swepub:oai:research.chalmers.se:dba13e4b-207a-46bc-b71b-ee7ee759181d" > Leveraging high-res...

  • Limeta, Angelo,1996Chalmers tekniska högskola,Chalmers University of Technology (författare)

Leveraging high-resolution omics data for predicting responses and adverse events to immune checkpoint inhibitors

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • 2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:research.chalmers.se:dba13e4b-207a-46bc-b71b-ee7ee759181d
  • https://doi.org/10.1016/j.csbj.2023.07.032DOI
  • https://research.chalmers.se/publication/536993URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:153620002URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:for swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • A long-standing goal of personalized and precision medicine is to enable accurate prediction of the outcomes of a given treatment regimen for patients harboring a disease. Currently, many clinical trials fail to meet their endpoints due to underlying factors in the patient population that contribute to either poor responses to the drug of interest or to treatment-related adverse events. Identifying these factors beforehand and correcting for them can lead to an increased success of clinical trials. Comprehensive and large-scale data gathering efforts in biomedicine by omics profiling of the healthy and diseased individuals has led to a treasure-trove of host, disease and environmental factors that contribute to the effectiveness of drugs aiming to treat disease. With increasing omics data, artificial intelligence allows an in-depth analysis of big data and offers a wide range of applications for real-world clinical use, including improved patient selection and identification of actionable targets for companion therapeutics for improved translatability across more patients. As a blueprint for complex drug-disease-host interactions, we here discuss the challenges of utilizing omics data for predicting responses and adverse events in cancer immunotherapy with immune checkpoint inhibitors (ICIs). The omics-based methodologies for improving patient outcomes as in the ICI case have also been applied across a wide-range of complex disease settings, exemplifying the use of omics for in-depth disease profiling and clinical use.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gatto, Francesco,1987Karolinska Institutet,Chalmers tekniska högskola,Chalmers University of Technology(Swepub:cth)gatto (författare)
  • Herrgard, M. J.BioInnovation Institute (BII) (författare)
  • Ji, Boyang,1983BioInnovation Institute (BII)(Swepub:cth)boyang (författare)
  • Nielsen, Jens B,1962Chalmers tekniska högskola,Chalmers University of Technology,BioInnovation Institute (BII)(Swepub:cth)nielsenj (författare)
  • Chalmers tekniska högskolaKarolinska Institutet (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Computational and Structural Biotechnology Journal21, s. 3912-39192001-0370

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy